Skip to main content

Clinical Trials Using Obinutuzumab

Review the clinical trials studying obinutuzumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-49 of 49

Mosunetuzumab or Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphoma After Receiving CAR T-cell Therapy
Status: Active
Location: 2 locations
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Status: Active
Location: 3 locations
Glofitamab with Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients with Newly Diagnosed High Risk Mantle Cell Lymphoma
Status: Active
Location: 2 locations
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Status: Active
Location: 2 locations
Testing the Anti-cancer Drug, Glofitamab, in Patients with Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned after CAR-T Cell Therapy
Status: Active
Location: JHU Sidney Kimmel Comprehensive Cancer Center LAO, Baltimore, Maryland
Acalabrutinib and Venetoclax with or without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Pirtobrutinib, Venetoclax, and Obinutuzumab for the Treatment of Untreated Chronic Lymphocytic Leukemia or Untreated, Recurrent, or Refractory Richter Transformation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Obinutuzumab and CC-99282 for the Treatment of Patients with Previously Untreated High Tumor Burden Follicular Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Pirtobrutinib, Venetoclax, and Obinutuzumab for the Treatment of Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Glofitamab and Axicabtagene Ciloleucel as Second-Line Treatment for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Glofitamab Plus Ibrutinib with Obinutuzumab for the Treatment of Patients with Mantle Cell Lymphoma, IGNITE MCL Trial
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Glofitamab with Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Genetically Engineered Cells (LMY-920) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib, Venetoclax, and Obinutuzumab for the treatment of Relapsed or Refractory and Previously Untreated Mantle Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 4 locations
Tazemetostat in Combination with Zanubrutinib and Rituximab or Obinutuzumab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia or Follicular Lymphoma, TARZAN Trial
Status: Temporarily Closed to Accrual
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah